Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. - Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; et al. (Lancet Oncology, 2017)